Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies

Human Gene Therapy

Volumn 22, Issue 12, 2011, Pages 1587-1591

  Hoogduijn, M J ^a   Roemeling Van Rhijn, M ^a   Korevaar, S S ^a   Engela, A U ^a   Weimar, W ^a   Baan, C C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 15; INTERLEUKIN 2; RAPAMYCIN; SOTRASTAURIN; TACROLIMUS;

ADIPOSE TISSUE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL ACTIVATION; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOLOGY; INCUBATION TEMPERATURE; LYSIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL;

ADIPOSE TISSUE; CELL DEATH; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELLS; SIROLIMUS; TACROLIMUS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 83455206277     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.039     Document Type: Article

References (18)

1. Bouma, G.J., van der Meer-Prins, P.M., van Bree, F.P., et al. (1992). Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum. Immunol. 35, 85-92. (Pubitemid 23004569)
2. Crop, M.J., Baan, C.C., Korevaar, S.S., et al. (2009). Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 87, 896-906.
3. Crop, M.J., Korevaar, S.S., de Kuiper, R., et al. (2011). Human mesenchymal stem cells are susceptible to lysis by CD8+ T-cells and NK cells. Cell Transplant. (in press).
4. Eissens, D.N., van der Meer, A., van Cranenbroek, B., et al. (2010). Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell pheno-type. Am. J. Transplant. 10, 1981-1990.
5. Griffin, M.D., Ritter, T., and Mahon, B.P. (2010). Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum. Gene Ther. 21, 1641-1655.
6. Hoogduijn, M.J., Crop, M.J., Peeters, A.M., et al. (2007). Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev. 16, 597-604. (Pubitemid 47378732)
7. Hoogduijn, M.J., Crop, M.J., Peeters, A.M., et al. (2009). Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am. J. Transplant. 9, 222-230.
8. Lanier, L.L. (2008). Up on the tightrope: Natural killer cell activation and inhibition. Nat. Immunol. 9, 495-502. (Pubitemid 351560518)
9. Morigi, M., Introna, M., Imberti, B., et al. (2008). Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 26, 2075-2082.
10. Nauta, A.J., Westerhuis, G., Kruisselbrink, A.B., et al. (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108, 2114-2120. (Pubitemid 44395028)
11. Pal, R., Gopinath, C., Rao, N.M., et al. (2010). Functional recovery after transplantation of bone marrow-derived human mesen-chymal stromal cells in a rat model of spinal cord injury. Cytotherapy 12, 792-806.
12. Popp, F.C., Eggenhofer, E., Renner, P., et al. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ al-lografts in synergy with low-dose mycophenolate. Transpl. Immunol. 20, 55-60.
13. Pradier, A., Passweg, J., Villard, J., and Kindler, V. (2011). Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity. Cell Transplant. 11, 681-691.
14. Sbano, P., Cuccia, A., Mazzanti, B., et al. (2008). Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch. Dermatol. Res. 300, 115-124.
15. Spaggiari, G.M., Capobianco, A., Becchetti, S., et al. (2006). Me-senchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484-1490. (Pubitemid 43242385)
16. Sudres, M., Norol, F., Trenado, A., et al. (2006). Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 176, 7761-7767. (Pubitemid 43849077)
17. Togel, F., Hu, Z., Weiss, K., et al. (2005). Administered mesen-chymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 289, F31-F42. (Pubitemid 40863570)
18. Van Besouw, N.M., van der Mast, B.J., de Kuiper, P., et al. (2000). Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 70, 136-143. (Pubitemid 30490767)